TScan Therapeutics — Third Quarter 2026 Earnings Summary

TScan Therapeutics announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors, advancing candidates targeting PRAME and MAGE-A4 through IND-enabling studies with a goal to dose the first patient in the fourth quarter of 2027. The company paused further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 for heme malignancies due to insufficient capital and is actively seeking strategic partners for both this and its autoimmunity programs. For the third quarter of 2026, TScan reported revenue of $0.6 million and a net loss of $33.1 million, with cash and cash equivalents of $73.0 million expected to fund operations into the fourth quarter of 2027.